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IL-17 induced NOTCH1 activation in
oligodendrocyte progenitor cells enhances
proliferation and inﬂammatory gene expression
Chenhui Wang1,2,3,*, Cun-Jin Zhang2,4,*, Bradley N. Martin2,5,*, Katarzyna Bulek2, Zizhen Kang2,6, Junjie Zhao2,
Guanglin Bian2, Julie A. Carman7, Ji Gao7, Ashok Dongre7, Haibo Xue8, Stephen D. Miller9, Youcun Qian10,11,
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NOTCH1 signalling contributes to defective remyelination by impairing differentiation of
oligodendrocyte progenitor cells (OPCs). Here we report that IL-17 stimulation induces
NOTCH1 activation in OPCs, contributing to Th17-mediated demyelinating disease.
Mechanistically, IL-17R interacts with NOTCH1 via the extracellular domain, which facilitates
the cleavage of NOTHC1 intracellular domain (NICD1). IL-17-induced NOTCH1 activation
results in the interaction of IL-17R adaptor Act1 with NICD1, followed by the translocation of
the Act1–NICD1 complex into the nucleus. Act1–NICD1 are recruited to the promoters of
several NOTCH1 target genes (including STEAP4, a metalloreductase important for inﬂam-
mation and cell proliferation) that are speciﬁcally induced in the spinal cord by Th17 cells.
A decoy peptide disrupting the IL-17RA–NOTCH1 interaction inhibits IL-17-induced NOTCH1
activation and attenuates Th17-mediated experimental autoimmune encephalitis (EAE).
Taken together, these ﬁndings demonstrate critical crosstalk between the IL-17 and NOTCH1
pathway, regulating Th17-induced inﬂammatory and proliferative genes to promote demye-
linating disease.
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M
ultiple sclerosis (MS) is an inﬂammatory demyelinating
disease of the central nervous system (CNS) that
exhibits the histopathologic hallmarks of inﬂammation,
demyelination and neurodegeneration1. While the precise
mechanisms of MS pathogenesis have not been fully elucidated,
current models posit that myelin-reactive T helper cell
populations play a central role in the initiation and propagation
of the pathological process2–4. Experimental autoimmune
encephalomyelitis (EAE) is a widely used animal model of MS,
and elegant studies employing this model have deﬁned the series
of pathogenic events that occur in different phases of EAE/MS
development5,6. In the initiation stage of EAE, antigen-presenting
cells in the draining lymph nodes are activated and produce
cytokines that regulate the differentiation and proliferation of
effector CD4 T cells, including the T helper 1 (Th1) and T helper
17 (Th17) cell lineages. Th1 cells are functionally deﬁned by their
production of IFN-g and TNF-a, while Th17 cells produce IL-17,
IL-21 and IL-22 (refs 7,8). It was recently reported that auto-
reactive Th1 and Th17 cells are capable of independently
inducing EAE through what appears to be distinct effector
mechanisms9,10. Th17 cells are generated as a discrete lineage
when naive CD4þ T cells are activated in the presence of
transforming growth factor b (TGF-b) and IL-6, and they acquire
the ability to rapidly expand in the presence of IL-23 (refs 11–13).
While Th17 cells are known to produce a number of key pro-
inﬂammatory cytokines, IL-17 signalling is required for the
effector stage of Th17-mediated EAE because genetic ablation of
either IL-17 or IL-17 receptor renders mice resistant to EAE
development14,15. However, the precise cellular and molecular
basis by which IL-17 participates in the pathogenesis of MS/EAE
is still unclear.
Act1 is a key adaptor molecule in the IL-17 signalling pathway,
and propagates IL-17 downstream signalling events following
ligand stimulation16,17. We previously reported that deletion of
Act1 from the neuroectodermal lineage in mice (neurons,
oligodendrocytes and astrocytes) results in attenuated severity
of EAE18. We examined the cellular basis of this observation. The
disease course of EAE was unaffected by deletion of Act1 in
neurons or mature oligodendrocytes, and Act1 deletion in
astrocytes only modestly affected the disease course. Deletion of
Act1 in oligodendrocyte progenitor cells (OPCs) resulted in
markedly reduced EAE severity19. While IL-17 induced
characteristic inﬂammatory mediator expression in OPCs, IL-17
also exhibited strong inhibitory effects on the maturation of
oligodendrocyte lineage cells in vitro19. These data identify OPCs
as the major CNS cellular target of IL-17 in EAE.
The NOTCH signalling pathway is an evolutionarily conserved
pathway that regulates developmental processes in both inverte-
brates and vertebrates20,21. The majority of studies demonstrating
the involvement of the NOTCH pathway in the pathogenesis of
EAE have focused on the role of NOTCH in regulating T helper
cell maturation and effector cell differentiation22–25. The
NOTCH pathway has been shown to control OPC
differentiation and proliferation. Speciﬁcally, NOTCH activation
in OPCs was shown to contribute to defective remyelination in
the CNS by impairing the differentiation of OPCs into mature
oligodendrocytes26. Interestingly, our previous study showed that
selective Act1 deﬁciency in OPCs (NG2þ /Olig2þ ) confers
protection against EAE, and IL-17 treatment in vitro inhibits
OPC differentiation and reduces OPC survival19. However, the
precise molecular mechanism mediating this effect has remained
undeﬁned. Here we report that IL-17 treatment of OPCs
co-cultured with astrocytes leads to NOTCH1 activation in
OPCs and that this novel signalling cascade is dependent on the
extracellular domains of both IL-17 receptor and NOTCH1.
IL-17-induced NOTCH1 activation resulted in formation of the
Act1–NICD1 complex, translocation of Act1–NICD1 to the
nucleus and recruitment of Act1 and the transcription factor
RBP-J to the promoters of several NOTCH target genes that are
important for inﬂammation and cell proliferation. As a result, IL-
17-induced NOTCH1 activation in OPCs promoted the
inﬂammatory response, cell proliferation and inhibited OPC
maturation. Further underlining the pathogenic signiﬁcance of
IL-17-induced NOTCH1 activation, selective genetic ablation of
either NOTCH1 or RBP-J in OPCs was sufﬁcient to greatly
attenuate the development and severity of Th17- but not Th1-
mediated EAE. Moreover, intracerebroventricular injection of a
decoy peptide based on the sequence of IL-17RA greatly inhibited
IL-17-induced NOTCH1 activation and attenuated Th17-
mediated EAE.
Results
Act1 directly interacts with NOTCH1 via NICD1. To identify
novel interacting partners of Act1, we immunoprecipitated
endogenous Act1 in the lysates of Hela cells treated with IL-17,
followed by mass spectrometric analysis of the proteins that were
co-immunoprecipitated with Act1. Several NOTCH family
member proteins were detected, including NOTCH1, NOTCH2
and NOTCH3 (Supplementary Fig. 1). Since Act1 interacted most
strongly with NOTCH1, we decided to focus on the Act1–
NOTCH1 interaction. The interaction of Act1 with NOTCH1
was conﬁrmed by co-immunoprecipitation followed by western
blot analysis (Fig. 1a). Structure-function analysis indicated that
Act1 interacts with the intracellular domain (NICD1) but not the
extracellular domain (NECD1) of NOTCH1 (Fig. 1b). We further
examined the Act1–NICD1 interaction by imaging analysis fol-
lowing transfection with GFP- or RFP-tagged proteins (Fig. 1c).
When co-expressed with NECD1 (GFP), Act1 (RFP) was pri-
marily located in the cytoplasm and did not co-localize with
NECD1. In dramatic contrast, Act1 co-localized with NICD1 in
the nucleus (Fig. 1c). To visualize the interaction between Act1
and NOTCH1/NICD1, we performed an in situ proximity liga-
tion assay (PLA) using IL-17RA as a positive control. We detected
a strong signal for the Act1–NOTCH1 complex in the cytoplasm
and the Act1–NICD1 interaction in the nucleus (Fig. 1d).
On ligand binding, the NOTCH1 receptor is cleaved by ADAM
family metalloproteases followed by the intramembrane
g-secretase complex to generate NICD1, which translocates into
the nucleus to convert the DNA-binding protein RBP-J from a
transcriptional repressor into an activator. This process involves
the formation of a stable complex consisting of NICD1, RBP-J
and Mastermind-like family of co-activators (MAML), and it
serves as a platform for the further recruitment of other co-
activators to activate NOTCH1 target genes20,21. Given our
ﬁnding that Act1 could bind directly to NICD1, we further tested
whether Act1 had any impact on the NOTCH1 pathway. We
found that Act1 was able to increase NOTCH1 target gene Hes1-
driven reporter activity in a dose-dependent manner when co-
expressed with NICD1 (Fig. 1e), suggesting that Act1 might play
a positive role in the NOTCH1 pathway through its interaction
with NICD1. Since Act1 is a U-box-containing E3 ligase27 and
NICD1 is known to be regulated by ubiquitination28,29, we next
examined whether the E3 ligase activity of Act1 is required for its
impact on NICD1 activity. We found that the Act1 E3 mutant
(DU-box) lost the ability to translocate into the nucleus
(Supplementary Fig. 2a) due to defective binding to NICD1
(Supplementary Fig. 2b). As a result, the Act1 E3 mutant failed to
promote NICD1 activity compared with wild-type Act1
(Supplementary Fig. 2c). Interestingly, Act1 induced K63-linked
polyubiquitination of NICD1 (Supplementary Fig. 2d). Taken
together, these results suggest that the E3 ligase activity is
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required for its ability to promote NICD1 activity, probably by
ubiquitinating NICD1. Since the Act1 E3 mutant (DU-box) failed
to interact with NICD1, Act1-mediated NICD1 ubiquitination
might be critical for the stability of the Act1–NICD1 complex. To
further understand the mechanism by which Act1 facilities
NICD1 activity, we examined the possible impact of Act1 on
NICD1–RBP-J complex formation and the recruitment of
co-activators including MAML1, P300 and PCAF. Interestingly,
Act1 was detected in the RBP-J–NICD1 complex, and
overexpression of Act1 increased the recruitment of MAML1,
P300 and PCAF to the Act1–NICD1–RBP-J complex (Fig. 1f).
Collectively, these ﬁndings suggest that Act1 directly binds to
NOTCH1 through NICD1 and ubiquitinates NICD1 to form a
stable complex with NICD1–RBP-J in the nucleus, facilitating the
recruitment of co-activators for gene transcription.
IL-17 activates the NOTCH pathway in OPC-astrocyte
co-cultures. Our previous study revealed that the pathogenic
impact of IL-17 signalling during neuroinﬂammation is most
critical in NG2þ OPCs, as selective genetic ablation of Act1 in
OPCs but not in other neuroglial populations, ameliorated the
Th17-mediated EAE phenotype19. In that study, IL-17 was also
shown to inhibit OPC differentiation while promoting OPC
proliferation through an unclear mechanism19. It is well
established that the NOTCH1 pathway controls the
differentiation and proliferation of OPCs, and NOTCH1
signalling has also been shown to modulate demyelination/
remyelination in mouse models of inﬂammatory demyelinating
disease26,30. Collectively, these ﬁndings prompted us to examine
the possibility that IL-17 might affect the NOTCH1 pathway in
OPCs. Treatment of OPCs with IL-17 for different time periods
had no observable impact on NOTCH1 activation, as assessed by
production of the NOTCH1 cleavage product NICD1 (Fig. 2a).
An earlier study suggested that TGF-b acts on astrocytes to
promote expression of the NOTCH1 ligand Jagged1, thereby
activating NOTCH1 in OPCs and inhibiting their
differentiation26. Consistent with the previous report, we
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Figure 1 | Act1 directly interact with NOTCH1 through NICD1. (a) HEK293 cells were transfected with HA–Act1 alone or in combination with FLAG-
NOTCH1. Cell lysates were immunoprecipitated with anti-FLAG antibody, followed by immunoblot analysis for indicated proteins. (b) HEK293 cells were
transfected with GFP–NICD1, GFP–NECD1 and HA–Act1 alone or in combination as indicated. Cell lysates were immunoprecipitated with anti-HA antibody,
followed by immunoblot analysis for the indicated proteins. Asterisk indicates non-speciﬁc band. (c) HeLa cells were transfected with GFP–NOTCH1, GFP–
NICD1, GFP–NECD1 and RFP–Act1 as indicated. Images were acquired using confocal microscopy under a 60 objective; scale bar, 20mm. Frequencies of
cells showing Act1–NICD co-localization in the nuclei in the total RFP-positive cells are shown in bar graphs. (d) HeLa cells were transfected with HA–Act1
alone or in combination with indicated plasmids. In situ PLA was performed by using rabbit anti-FLAG and mouse anti-HA antibodies followed by proximity
ligation (see Methods section) and DAPI staining. Red: PLA signal indicating protein–protein interaction; blue: nuclei. Images were acquired using confocal
microscopy under a  60 objective; scale bar, 20mm. Frequencies of PLA-positive cells are shown in bar graphs. (e) HeLa cells were transfected with Hes1-
luciferase reporter (100 ng) alone or with indicated combinations of human NICD cDNA (200ng) and increasing amounts of human Act1 cDNA (0, 100,
200 and 500 ng). Data are plotted as fold induction of luciferase activity from cells with indicated transfection over that of the Hes1-luciferase transfection
alone. (f) HEK293 cells were transfected with FLAG–NICD1 (3 mg) with increasing amounts of HA–Act1 (3 and 6mg). Cell lysates were immunoprecipitated
with anti-FLAG (upper panel) or anti-RBP-J antibody (lower panel), followed by immunoblot analysis for the indicated antibodies. IgG, immunoglobulin G;
IB, immunoblotting; IP, immunoprecipitation; WCL, whole-cell lysates. Arrow indicates the band for FLAG–NICD1. *Po0.05 based on Mann–Whitney
U-test. All error bars represent s.e.m. of technical replicates. Data are representative of three independent experiments.
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detected an increase in NICD1 cleavage in OPCs co-cultured with
astrocytes following stimulation with TGF-b. Intriguingly, IL-17
also induced NICD1 cleavage in this co-culture system, and
treatment with IL-17þTGF-b resulted in enhanced NICD1
production compared with IL-17 or TGF-b treatment alone
(Fig. 2b). One possible explanation for NOTCH1 pathway
activation in this system was that IL-17 might upregulate
Jagged1 expression in astrocytes, thus indirectly activating
NOTCH1 in nearby OPCs. However, analysis of an astrocyte
monoculture revealed that while stimulation with TGF-b
treatment or IL-6 upregulated expression of Jagged1, there was
no change in Jagged1 expression in response to IL-17 treatment
(Fig. 2c). We also examined whether IL-17 might upregulate
other NOTCH pathway ligands in astrocytes and found that IL-
17 did not have any impact on the expression of the other
NOTCH ligands (Supplementary Fig. 3). Taken together, these
results suggested that IL-17 stimulation might have a direct
impact on the activation of NOTCH1 in OPCs co-cultured with
astrocytes.
Cleavage of NICD1 in response to NOTCH receptor ligation is
a g-secretase-dependent process. Pre-treatment with DAPT
(a g-secretase inhibitor) abolished IL-17-induced cleavage of
NICD1 at all tested time points, suggesting that IL-17-induced
NOTCH activation is also g-secretase dependent (Fig. 2d, left
panel). Notably, IL-17-induced NICD1 cleavage was abolished in
a co-culture containing NOTCH1 KO OPCs, suggesting that IL-
17-induced NOTCH1 activation is intrinsic to OPCs (Fig. 2d,
right panel). Supporting this ﬁnding, co-culture of wild-type
OPCs with NOTCH1 KO astrocytes had no signiﬁcant impact on
IL-17-induced NICD cleavage (Fig. 2e). Likewise, NOTCH1
activation was completely abolished in a co-culture containing
IL-17RA KO OPCs (Fig. 2f). However, consistent with the
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observation that IL-17-induced NOTCH1 activation in OPCs
required astrocyte co-culture, IL-17-induced NICD cleavage was
completely abolished in the co-culture of OPCs with Jagged1 KO
astrocytes, indicating that astrocytes expressing Jagged1 were
indispensable for IL-17-induced NOTCH activation in OPCs
(Fig. 2g).
Given that Act1 directly interacts with the intracellular domain
of NOTCH1, the next question was whether Act1 is required for
IL-17-induced NICD1 cleavage. Surprisingly, Act1 deﬁciency in
OPCs co-cultured with astrocytes resulted in a partial defect in
NICD1 cleavage in response to IL-17 treatment, which suggested
that IL-17-induced NICD1 cleavage was mediated mostly at the
receptor level and that Act1 played only a partial role in this
process (Fig. 2h). Interestingly, we found that while Act1 was
recruited to IL-17RA and NOTCH1 shortly after IL-17 stimula-
tion (30min), the NICD1–Act1 complex was only detected at 8 h
after IL-17 stimulation (Fig. 2i). The g-secretase-dependent
process probably accounted for the delay in NOTCH1 cleavage
after the IL-17-induced interaction of IL-17R–Act1 with
NOTCH1. The interaction of Act1 with IL-17RA was more
transient than its interaction with NOTCH1, implicating that
Act1 may stay with NOTCH1 to eventually form the Act1–
NICD1 complex.
IL-17RA–NOTCH1 interaction induces NICD cleavage. We
found that IL-17-induced NOTCH activation required NOTCH1,
IL-17 receptor and the NOTCH ligand Jagged1 (Fig. 2d,f,g),
suggesting that this activation might be initiated at the receptor
level. We next investigated whether there was any interaction
between IL-17 receptor and NOTCH1. Co-immunoprecipitation
and in situ PLA revealed that IL-17RA indeed formed a complex
with NOTCH1 (Fig. 3a,b), and this interaction required the
extracellular domain of NOTCH1 (NECD1) (Fig. 3c). Thus, we
hypothesized that the interaction of IL-17R and NOTCH1 via the
extracellular domain facilitates the cleavage of NICD1; Act1–
NICD1 then forms a complex and translocates into the nucleus.
In support of this hypothesis, IL-17 stimulation indeed induced
nuclear translocation of NICD1 and Act1 in OPC-astrocyte co-
culture (wild-type OPCs with IL-17RA KO astrocytes), which
was blocked by N-[(3,5-Diﬂuorophenyl)acetyl]-L-alanyl-2-phe-
nyl]glycine-1,1-dimethylethyl ester (DAPT) (a g-secretase inhi-
bitor) (Fig. 3d). This result suggested that the cleavage of NICD1
was necessary for Act1–NICD1 nuclear translocation. Con-
sistently, while Jagged1 expressed by astrocytes was required for
IL-17-induced NOTCH1 cleavage in the co-culture system,
NICD1 and Act1 nuclear translocation were abolished in OPCs
co-cultured with Jagged1 KO astrocytes (Supplementary Fig. 4).
The ﬁnding that IL-17RA directly interacted with NOTCH1
prompted us to carefully analyse the protein regions mediating
this interaction. We found that deletion of the extracellular
domain of IL-17RA (IL-17RA D33–320) completely abolished the
interaction between IL-17RA and NECD1, indicating that the IL-
17R–NOTCH1 interaction occurred via their extracellular
domains (Fig. 3e). Furthermore, sequential deletion analysis of
IL-17RA demonstrated that removal of two small regions within
the extracellular domain of IL-17RA (D133–183; D283–320)
greatly reduced the IL-17RA–NECD1 interaction (Fig. 3e).
NICD1–Act1 translocates into the nucleus of OPCs during
EAE. To examine whether IL-17 could induce NOTCH1 activa-
tion and Act1–NICD1 nuclear translocation in vivo, we generated
a ﬂoxed HA-tagged Act1 knock-in mouse (into its own locus),
which enabled us to track endogenous Act1 cellular localization
in vivo in a cell-type-speciﬁc manner (Fig. 4a). By breeding this
mouse line to a PDGFRa-CRE (speciﬁcally expressed in OPCs)
transgenic mouse, we obtained an OPC-speciﬁc HA–Act1 knock-
in mouse line (Fig. 4b), which was used to track NOTCH1 acti-
vation and Act1 cellular localization in the CNS system in a
model of Th17 adoptive transfer-induced EAE (Fig. 4a). By
immunoﬂuorescence staining, we observed that Act1 was mainly
expressed in the cytoplasm of OPCs (PDGFRaþ cells) in the
brain of naive mice (Fig. 4b). Interestingly, 6 days after Th17
adoptive transfer, Act1 was predominantly localized in the nuclei
of OPCs (PDGFRaþ cells) (Fig. 4b). Moreover, we detected
robust NICD1 staining in the nuclei of OPCs and perfect Act1–
NICD1 nuclear co-localization (Fig. 4c). These data provided
in vivo evidence for the function of the IL-17/Act1/NOTCH1 axis
in OPCs during the course of EAE.
IL-17 induces a subset of NOTCH1-dependent genes in OPCs.
IL-17 activates the NF-kB and MAPK pathways, thereby inducing
inﬂammatory gene expression. Furthermore, IL-17-mediated pro-
inﬂammatory gene expression has been shown to be important in
many disease states, including MS/EAE. Given the surprising
ﬁnding that IL-17 can also induce NOTCH1 activation in OPCs,
we sought to determine whether this novel IL-17–NOTCH1 axis
plays any role in EAE pathogenesis. Th1- or Th17-polarized
myelin oligodendrocyte glycoprotein (MOG)-reactive T cells were
adoptively transferred to a naive recipient. At the peak of EAE
disease, microarray analysis of gene expression was conducted on
recipient spinal cords. Bioinformatics analysis revealed that a
number of genes were speciﬁcally induced in Th17 cell-recipient
spinal cords (Fig. 5a). We found that IL-17 stimulation was able
to induce these Th17-speciﬁc genes in wild-type OPCs co-cul-
tured with Act1 KO astrocytes, but not in the co-culture of Act1
KO OPCs (Fig. 5b). Interestingly, the induction of these Th17-
speciﬁc genes was abolished in NOTCH1 KO OPC co-cultures,
including the inﬂammatory genes CXCL1, STEAP4, PTX3,
S100A9, CCL7 and CP (Fig. 5c). With the exception of STEAP4,
all of these gene products have previously been implicated in the
pathogenesis of MS/EAE. It is important to note that, compared
with the astrocytes-OPC co-culture, IL-17 stimulation of OPCs
alone induced much lower levels of expression of the IL-17-
induced genes indicated above (Supplementary Fig. 5a). As a
control, we showed that TGF-b failed to upregulate these IL-17-
induced genes in an astrocyte-OPC co-culture. However, whereas
Hes5 and Hes7 were highly induced by TGF-b in a NOTCH1-
dependent manner, these two genes were not induced by IL-17 in
astrocyte-OPC co-culture (Supplementary Fig. 5b,c).
Since IL-17 induces the nuclear translocation of the Act1–
NICD1 complex, we next questioned whether Act1–NICD1 could
form a complex with RBP-J on the promoters of those Th17-
induced NOTCH targets. Co-immunoprecipitation showed that
IL-17 stimulation indeed induced the interaction of Act1 with
NICD1 and RBP-J in OPC co-cultures (wild-type OPCs with
Act1 KO astrocytes) (Fig. 6a). Chromatin immunoprecipitation
analysis of IL-17-treated OPC co-cultures (wild-type OPCs with
Act1 KO astrocytes) demonstrated that RBP-J was recruited to
the promoter region of STEAP4, PTX3, S100A9 and CCL7 in
response to IL-17 stimulation. However, we did not observe
recruitment of RBP-J to the promoter of CXCL1 or CP. These
ﬁndings suggest that STEAP4, PTX3, S100A9 and CCL7 are
direct target genes of the IL-17–NOTCH axis, while CXCL1 and
CP expression might be regulated by an indirect mechanism
(Fig. 6b). These ﬁndings prompted us to examine the recruitment
of Act1 to the STEAP4, PTX3, S100A9 and CCL7 promoter
regions in IL-17-treated OPCs co-cultures (wild-type OPCs with
Act1 KO astrocytes). Indeed, mirroring what we observed with
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the NOTCH transcription factor RBP-J, Act1 was also recruited
to the promoter region of these genes in response to IL-17
treatment (Fig. 6b). Notably, the IL-17-induced recruitment of
Act1 to these promoters was completely blocked by the g-
secretase inhibitor DAPT (Fig. 6c), indicating that Act1 binding
to the Th17-induced NOTCH target genes was dependent on
NOTCH activation/cleavage followed by the NICD1–Act1
interaction and nuclear translocation.
It is important to note that some of the Th17-induced NOTCH
target genes, such as STEAP4 and S100A9, actually have dual roles
in inﬂammatory and proliferative responses31–35. STEAP4, a
metalloreductase with NADPH oxidase (NOX) activity, has been
reported to play a role in cell metabolism and cell proliferation.
IL-17-induced STEAP4 expression was indeed found to promote
keratinocyte proliferation31. Thus, we wondered whether STEAP4
might also play a role in OPC proliferation and differentiation.
We knocked down STEAP4 expression in OPCs by lentiviral
shRNA, and then examined cell proliferation and differentiation
in co-culture with IL-17RA KO astrocytes. STEAP4 knockdown
attenuated IL-17-induced OPC proliferation and reversed IL-17-
mediated inhibition of OPC differentiation (Fig. 6d). These data
suggest that the role of IL-17 in OPC proliferation and
differentiation might be at least partially dependent on STEAP4
induction.
Ablation of NOTCH1 in OPCs ameliorates Th17-induced EAE.
The IL-17–NOTCH axis-induced genes identiﬁed in this study
have previously been implicated in the pathogenesis of
MS/EAE36,37. Therefore, we hypothesized that OPC-intrinsic
NOTCH1 might critically impact Th17-mediated EAE
development. To test this hypothesis, we generated
NG2ER-CreNOTCH1f/þ and NG2 ER-CreNOTCH1f/f mice to
speciﬁcally ablate NOTCH1 expression in NG2þ OPCs.
Immunoﬂuorescence conﬁrmed the efﬁcient deletion of
NOTCH1 in NG2þ OPC cells of the spinal cord after
induction of NOTCH1 depletion by tamoxifen. Interestingly, it
seemed that all the NG2þ OPC cells expressed NOTCH1 based
on immunoﬂuorescent staining (Fig. 7a). MOG-reactive Th17
cells were then adoptively transferred into sublethally irradiated
NG2ER-CreNOTCH1f/þ and NG2ER-CreNOTCH1f/f recipient mice,
which showed that the severity of Th17 cell-induced EAE was
greatly reduced in NG2ER-CreNOTCH1f/f mice compared with the
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control mice (Fig. 7b). Analysis of brain-inﬁltrating mono
nucleus cell populations revealed that NG2ER-CreNOTCH1f/f
mice had fewer inﬁltrating CD4þ cells, macrophages,
neutrophils and B cells compared with the control mice
(Fig. 7c). Histopathological analysis mirrored these ﬁndings,
with reduced inﬂammatory inﬁltration and demyelination
observed in spinal cords from NG2ER-CreNOTCH1f/f mice
(Fig. 8a). Notably, the expression of genes that were directly
controlled by the IL-17–NOTCH1 axis (CXCL1, STEAP4 and
PTX3) was greatly reduced in spinal cords from NG2ER-
CreNOTCH1f/f recipients compared with the controls (Fig. 8b).
In a previous study, we reported that following adoptive
transfer of MOG-reactive Th17 cells, the NG2þ OPC cell
population was expanded in the CNS of wild-type mice, but not
in NG2CreAct1f/ mice19. Therefore, we speculated that IL-17-
induced NOTCH1 activity might have contributed to this
phenotype since the NOTCH pathway is known to promote
OPC proliferation and interfere with OPC differentiation26.
During Th17-mediated EAE, the percentage of Ki67þNG2þ and
PDGFRaþ OPC cells was signiﬁcantly higher in the spinal cords
of control mice than in NG2ER-CreNOTCH1f/f mice (Fig. 8c,d).
These results suggest that IL-17–Act1–NOTCH1 signalling may
promote OPC proliferation, thereby attenuating the proper
maturation of OPCs required for the remyelination process
after Th17-induced demyelination. In support of this ﬁnding, the
matured oligodendrocytes (GST-pþ cells) were indeed highly
reduced in the control mice compared to with the
NG2ER-CreNOTCH1f/f mice (Fig. 8d). To test whether NOTCH
activation plays a speciﬁc role in Th17-mediated EAE, we
adoptively transferred MOG-reactive Th1 cells into sublethally
irradiated NG2CreNOTCH1f/þ and NG2ER-CreNOTCH1f/f
recipient mice. NG2-speciﬁc NOTCH1 deletion did not result
in a noticeable impact on TH1-induced EAE, including the
clinical score, cell inﬁltration or gene expression, further
highlighting the role of NOTCH activation in the IL-17
pathway in OPCs (Supplementary Fig. 6).
In addition to NOTCH1, we also found that Act1 co-
immunoprecipitated with NOTCH2 and NOTCH3 based on
MS spectrum identiﬁcation (Supplementary Fig. 1). Additionally,
microarray analysis revealed that NOTCH2 was also induced in
the spinal cords of mice receiving MOG-reactive Th17 cells
(Supplementary Data 1). Given that RBP-J is a common
transcription factor for all NOTCH members, we generated
NG2ER-CreRBP-Jf/þ and NG2ER-CreRBP-Jf/f mice. Western blot
analysis showed that the expression of RBP-J was completely
ablated in NG2þ OPC cells derived from NG2CreRBP-Jf/f
(Supplementary Fig. 7a). Following the adoptive transfer of
MOG-reactive Th17 cells, the EAE phenotype was dramatically
reduced in NG2ER-CreRBP-Jf/f mice compared with the control
mice (Supplementary Fig. 7b). The impact of NG2-speciﬁc RBP-J
deletion on Th17-induced EAE was more substantial than that of
NG2-speciﬁc NOTCH1 deletion, implicating possible
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involvement of NOTCH2/3 in this IL-17–NOTCH axis during
Th17-induced EAE. However, NG2-speciﬁc RPB-J deletion did
not have a noticeable impact on Th1-induced EAE
(Supplementary Fig. 7c). Together, these data indicated that
NOTCH pathways other than NOTCH1 might also play a crucial
role in the pathogenesis of Th17-, but not Th1-mediated, EAE.
Disruption of the IL-17RA–NOTCH1 interaction attenuates
EAE. Based on surface-exposed regions of the sequence of a
protein, a decoy peptide may have the ability to bind to and
occupy the docking site of the interacting partner of the original
protein, interrupting the protein–protein interaction38. Our
deletion analysis showed that IL-17RA and NOTCH1 interacted
with each other via their extracellular domains, and amino-acid
residues 280–320 in IL-17RA were required for the interaction of
IL-17RA with NOTCH1 (Fig. 3e). To disrupt the interaction
between IL-17RA and NOTCH1, a decoy peptide (with a
ﬂuorescein isothiocyanate (FITC) tag at its C terminus) was
generated based on the sequence from 280–320 of IL-17RA (RA
peptide). As a control, we showed that the RA peptide did not
have any impact on IL-17-induced NF-kB and MAPK activation
(Fig. 9a), suggesting that this peptide probably does not interrupt
IL-17 binding to the receptor. Strikingly, the addition of RA
peptide greatly reduced IL-17-induced NOTCH activation
(NICD1 cleavage) in OPC co-culture with Act1 KO astrocytes
(Fig. 9b). The co-immunoprecipitation experiment showed that
this peptide interrupted IL-17RA and NOTCH1 binding (Fig. 9c).
Furthermore, the decoy peptide completely abolished IL-17-
induced inﬂammatory gene expression in OPCþ astrocyte co-
culture (Fig. 9d) and attenuated the IL-17-mediated impact on
OPC proliferation and differentiation (Fig. 9e).
To conﬁrm that the RA peptide could directly bind to
NOTCH1, we stained wild-type and NOTCH1 KO OPCs with
the decoy RA-peptide-FITC and NOTCH1 antibody. Flow
cytometry analysis showed that wild-type OPCs, but not
NOTCH1 KO OPCs, co-stained with NOTCH1 and RA-
peptide-FITC, implicating that this peptide could bind directly
to NOTCH1 (Fig. 7f). The residual NOTCH1-positive signalling
in the NOTCH1 KO sample might be due to incomplete
depletion of NOTCH1 by adenovirus expressing cre-mediated
depletion (Fig. 9f). Notably, most of the OPCs were NOTCH1
positive (Fig. 9f), which is consistent with the literature26 and the
data shown in Fig. 7a. Since this decoy peptide was efﬁcacious for
blocking IL-17-induced NOTCH1 activation in co-cultures
(without inhibition of TGF-b-induced NOTCH1 activation,
Supplementary Fig. 8), we next tested whether it had any
therapeutic effect on Th17-induced EAE. To overcome the
blood–brain barrier, we used an osmotic pump to continuously
deliver RA peptide into the CNS by intracerebroventricular
injection. Interestingly, the administration of RA peptide
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signiﬁcantly attenuated the Th17-mediated EAE severity (Fig. 9g),
reduced the CNS-inﬁltrated macrophages and neutrophils
(Fig. 9h) and decreased Th17-induced expression of NOTCH
genes in the spinal cord (Fig. 9i). Histopathological analysis also
indicated reduced inﬂammatory inﬁltration and demyelination in
spinal cords in the peptide-treated group (Fig. 9j). Thus, the RA
peptide has a potent therapeutic effect on Th17-mediated EAE,
probably by disrupting the IL-17RA–NOTCH axis in OPCs.
Discussion
In the present study, we report for the ﬁrst time that IL-17 crosstalks
with NOTCH1, a pathway that is known to promote OPC
proliferation and suppress OPC differentiation, contributing to
demyelinating disease. IL-17R interacts with NOTCH1 via the
extracellular domain, which facilitates the cleavage of NICD1,
formation of the Act1–NICD1 complex and subsequent transloca-
tion into the nucleus. As a result, Act1 and the transcription factor
RBP-J are recruited to the promoters of several Th17-induced
NOTCH1 target genes, such as STEAP4, which are critical for
inﬂammation and cell proliferation. Mechanistically, we found Act1
enhanced the interaction of NICD1 with co-activators of the
transcription factor RBP-J, thereby promoting expression of the
target genes. Selective genetic ablation of either NOTCH1 or RBP-J
in OPCs attenuated the development and severity of Th17- but not
Th1-mediated EAE. A decoy peptide of IL-17RA 280–320, which
was required for NOTCH–IL-17RA interaction, inhibited IL-17-
induced NOTCH1 activation, blocked the impact of IL-17 on the
OPC inﬂammatory response, proliferation and maturation, and
attenuated Th17-mediated EAE. Taken together, these ﬁndings
demonstrated that IL-17-induced NICD1–Act1 nuclear transloca-
tion promoted inﬂammatory gene induction in OPCs that enhanced
cell proliferation and interfered with OPC maturation, providing a
new mechanism for the IL-17 and NOTCH1 pathways in
demyelinating disease (Fig. 10).
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Act1 is a key adaptor molecular in IL-17 pathway and plays a
very important role in IL-17 signal transduction17. Herein, we
report for the ﬁrst time a nucleus function of Act1. On ligand
binding, NOTCH1 receptor is cleaved by ADAM family
metalloproteases, followed by intramembrane g-secretase
complex, generating NICD that translocates into nucleus to
convert the DNA-binding protein RBP-J from a transcriptional
repressor into an activator. This process involves the formation of
a stable complex which composes of NICD, RBP-J and
Mastermind-like family of co-activators (MAML), and the
complex serves as a platform to further recruit other co-
activators for the activation of NOTCH target genes20,21. We
now found that Act1 forms a complex with NICD–RBP-J and
increases the recruitment of co-activators MAML1, P300 and
PCAF to NICD–RBP-J. It is possible that in response to IL-17
treatment, Act1 might recruit additional co-activators to NICD–
RBP-J, directing NICD–RBP-J binding speciﬁcally to the Th17-
induced NOTCH target genes, including STEAP4, PTX3, S100A9
and CCL7 (Fig. 10).
In the present study, we found that IL-17 could not activate
NOTCH1 in OPC single culture conditions, but it could fully
activate NOTCH1 in OPCs co-cultured with astrocytes. Jagged1
expressed on astrocytes has been shown to inhibit OPC
differentiation and myelination26, making it a possible candidate
in the IL-17-induced NOTCH1 activation process. Indeed, the co-
culture of OPCs with Jagged1 KO astrocytes abolished IL-17-
induced NOTCH1 activation, indicating that Jagged1 is
indispensable for IL-17-induced NOTCH1 activation. One of the
key events in NOTCH activation is the release of the NOTCH
ectodomain through ligand-induced and ADAM-mediated
NOTCH cleavage at cleavage site S2. This cleavage site resides
within the negative regulatory region of NOTCH, which functions
to prevent NOTCH activation. Since our data showed that IL-17R
interacted with the extracellular domain of NOTCH1 (NECD1), it
is possible that the IL-17R–NECD1 interaction may disrupt the
inhibitory effect of the negative regulatory region of NOTCH1,
facilitating ADAM-mediated NOTCH1 cleavage at cleavage site S2
followed by cleavage at S3 and S4 by the intramembrane g-secretase
complex for NOTCH1 activation. Alternatively, the IL-17R–
NECD1 interaction may transduce the signal to the Notch1
transmembrane domain, directly promoting cleavage at S3 and S4
via the intramembrane g-secretase complex to release NICD1.
Future studies are required to elucidate the detailed molecular
mechanism by which the IL-17RA–NOTCH1 interaction promotes
NOTCH1 activation.
The Th17 and IL-17 pathways play an essential role in many
autoimmune diseases including MS39,40. Speciﬁc ablation of Act1,
NOTCH1 and RBP-J in OPCs greatly attenuated EAE
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Figure 7 | NOTCH1 deﬁciency in NG2þ OPCs attenuates Th17-induced EAE. (a) Transversal sections of lumbar spinal cords from mice of indicated
genotypes (n¼ 5) were stained with anti-NG2 (red) and anti-NOTCH1 (green) antibodies. Images were then acquired using confocal microscopy under a
 60 objective; scale bar, 20mm. Frequencies of NOTCH1 NG2þ cells were determined to assess deletion efﬁciency. (b) Mice of indicated genotypes were
adoptively transferred with MOG-reactive Th17 cells (n¼ 5) to induce EAE. Spinal cords were collected at peak of disease. Clinical scores of EAE symptoms
in mice described for a are graphed over the experimental time course. (Po0.0001 based on two-way ANOVA). (c) Inﬁltrating cells in the brains of mice
with Th17-induced EAE (n¼ 5) were isolated at the peak of the disease, followed by ﬂow cytometry analysis. The numbers of different inﬁltrating cells were
calculated for each mouse. All error bars represent s.e.m. of biological replicates. *Po0.05 based on Mann–Whitney U-test. Data are representative of
three independent experiments.
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development, suggesting that OPCs are the major CNS cellular
target of the IL-17 and NOTCH pathways in EAE19. While IL-17
induced a characteristic inﬂammatory response in OPCs ex vivo,
IL-17 also crosstalks with NOTCH1 to upregulate Th17-induced
NOTCH1 target genes that are important for both inﬂammation
and cell proliferation. The knowledge that most OPCs are
NOTCH1-positive suggests that IL-17RA–NOTCH crosstalk is
probably the dominant mode of OPC signalling in response to IL-
17 stimulation. In support of this hypothesis, RA peptide that
blocks IL-17RA–NOTCH1 interaction inhibited IL-17-induced
NOTCH1 activation and Th17-mediated EAE, indicating a
critical impact of the IL-17–NOTCH1 axis in Th17–IL-17-
dependent EAE pathogenesis. Based on our ﬁndings, we propose
that the IL-17/Act1/NOTCH axis has dual roles in progenitor
cells. While IL-17/NOTCH induces inﬂammatory gene
expression, it also promotes progenitor cell proliferation via
some of the target genes such as STEAP4. Both processes can be
inhibitory to the normal differentiation programme of the
progenitor cells (to become mature oligodendrocytes), resulting
in a lack of sufﬁcient remyelination (contributing to
demyelination). Future studies are required to carefully
determine the relative importance of NOTCH1 canonical versus
Th17-induced target genes in OPC proliferation/differentiation
and consequent demyelinating disease.
Methods
Mice. B6.129X1-Notch1tm2Rko/GridJ (stock number 006951), Jag1tm2Grid/J (stock
number 010618) and B6.Cg-Tg (Cspg4-cre/Esr1*) BAkik/J (stock number 008538)
were purchased from Jackson Laboratory. RBP-Jﬂ/ﬂ mice were provided by
Dr Tasuku Honjo and Dr Hu, Xiaoyu at Kyoto University and Tsinghua Uni-
versity. LSL–HA–Act1 knock-in mice were generated on a C57BL/6 background by
replacing exon 2 of Traf3ip2 with a LoxP-Stop-LoxP-Traf3ip2 cDNA-HA Tag-
PolyA cassette. All the mice used in this study were female. For all experiments, the
mice were age-matched (8–12 weeks) littermates between experimental groups.
The mice were housed under speciﬁc pathogen-free conditions. All animal studies
were approved by the Institutional Animal Care and Use Committee of Cleveland
Clinic.
Cells. The HEK293T and HeLa cell lines were obtained from the ATCC and
authenticated by analysing the morphology, growth curve and isoenzyme. Cells
were tested for mycoplasma contamination and were shown to be mycoplasma
negative. Both of these two cell lines were cultured in DMEM containing 10% heat-
inactivated FBS (foetal bovine serum, Gibco Cat: 10,438,026) and 1% pen/strep
(Thermo Fisher Scientiﬁc, Cat: 15,140,122).
Reagents. For immunoblot analysis, antibodies against NOTCH1, MAML1,
PCAF, RBP-J, NICD1, Jagged1, cleaved NOTCH1, rabbit control IgG, cleaved
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caspase-3, a-tubulin, H3, Myc, p-IkBa, p-p65, p-ERK, FLAG, HA and GFP were
purchased from Cell Signaling Biotechnology (CST, Cat No. 3,447, 11,959, 3,378,
5,313, 4,147, 2,620, 4,147, 3,900, 9,664, 3,873, 4,499, 2,276, 2,859, 3,033, 4,370,
14,793, 3,724 and 2,956); antibodies against Act1, P300, TRAF6 were purchased
from Santa Cruz Biotechnology (sc-11,444, sc-584 and sc-7,221); the antibody
against Actin was purchased from Sigma (A5,441); and the antibody against V5
was from Thermo Fisher Scientiﬁc (MA5-15,253). All antibodies were used at a
dilution of 1:1,000 for western blotting unless otherwise speciﬁed. For immuno-
ﬂuorescence, antibodies against FLGA and HA were purchased from CST (14,793)
and Sigma (H9,658), respectively; the antibody against NG2 was provided by W.B.
Stallcup (Burnham Institute for Medical Research); the antibody against Ki67 was
purchased from Abcam (Cat No. ab15,580); the antibody against cleaved NOTCH1
was from Abcam (ab8925); the antibody against GST-p was from CST (3,174) and
Enzo (ADI-MSA-102-E); and the antibody against PDGFRa was from eBioscience
(14-1,401-81). Antisera against STEAP4, IL-17RA or Act1 was generated by
Covance using selected peptides as immunogens. 4,6-Diamidino-2-phenylindole
(DAPI) was purchased from Sigma (D5942). All antibodies were used at a dilution
of 1:1,000 for western blotting unless otherwise speciﬁed.
Plasmids. Human NOTCH1 and Act1 cDNA were cloned into the pCDNA3.1
(þ ) vector with FLAG or HA sequences appended to the C terminus of the
protein. FLAG–GFP–NOTCH1, GFP–NICD1 and GFP–NECD1 plasmids were
kindly provided by Dr Valina L. Dawson at Johns Hopkins University School of
Medicine. FLAG–NICD1 was kindly provided by Dr Xiaoxu Hu at Tsinghua
University. FLAG and V5 tagged IL-17RA plasmids were generated by cloning
human IL-17RA into pCDNA3.1 (þ ) vector with V5 or FLAG sequence appended
to the C terminus. IL-17RA deletion mutants and Act1 deletion mutants were
constructed using a Quick Change mutagenesis kit from Agilent (200,518)
according to the manufacturer’s instruction. The primers used for mutagenesis are
listed in Supplementary Table 1.
Immunoblot and immunoprecipitation. Cells were collected and lysed on ice in
lysis buffer containing 0.5% Triton X-100, 20mM HEPES pH 7.4, 150mM NaCl,
12.5mM b-glycerophosphate, 1.5mM MgCl2, 10mM NaF, 2mM dithiothreitol,
1mM sodium orthovanadate, 2mM EGTA, 20mM aprotinin and 1mM phe-
nylmethylsulfonyl ﬂuoride for 20min, followed by centrifugation at 12,000 r.p.m.
for 15min to extract clear lysates. For immunoprecipitation, the cell lysates were
incubated with 1 mg of antibody and A-Sepharose beads at 4 C overnight. After
incubation, the beads were washed four times with lysis buffer, and the precipitates
were eluted with 2 sample buffer. The eluates and whole-cell extracts were
resolved by SDS–PAGE followed by immunoblotting with antibodies. Nuclear
fractionation was performed using the NUCLEI EZ PREP kit purchased from
Sigma in accordance with the manufacturer’s instructions. For cell fractionation,
we used the NUCLEI EZ PREP NUCLEI ISOLATION KIT from Sigma (Cat No.
NUC-101) to isolate nuclear and cytoplasmic proteins. Densitometric quantiﬁca-
tion of the western blot results was performed on images of scanned ﬁlms using
ImageJ software. All uncropped western blots can be found in Supplementary
Fig. 9.
Immunoﬂuorescence. Transfected cells or frozen sections were ﬁxed with 4%
paraformaldehyde (PFA) followed by permeabilization with PBS containing 0.3%
Triton X-100 for 10min. Before incubation with primary antibody, the samples
were incubated with 10% goat serum at room temperature for 1 h to block non-
speciﬁc staining. After 12 h of incubation with primary antibody at 4 C, the
samples were washed three times with ice-cold PBS and further stained with
ﬂuorophore (Alex488 and Alexa 530)-conjugated secondary antibodies. After
staining, the samples were counterstained with DAPI and immersed in mounting
medium before being sealed on a slide with nail polish. The sealed slides were
analysed using a Leica TCS-SP microscope with companion software. Quantiﬁ-
cation of immunoﬂuorescent staining was performed by manually enumerating the
number of positive cells in 20 views per biological or technical replicate.
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Figure 10 | Model of IL-17–NOTCH pathway. Left panel: canonical IL-17 signalling. IL-17 signals through a heterodimeric receptor complex composed of
IL-17RA and IL-17RC. On IL-17 stimulation, Act1 is recruited to IL-17R and subsequently engages TRAF6 and Hsp90 to activate NF-kB pathway. In addition,
IL-17 stimulation also promotes the formation of Act1–IKKi complex, which in turn engages TRAF2 and TRAF5 to activate the mRNA stabilization pathway.
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Mass spectrometry identiﬁcation. Samples were reduced and alkylated in
dithiothreitol and iodoacetamide followed by trypsin digestion overnight. Digested
samples were injected onto an Agilent Zorbax 300SB-C18 0.075mm 150mm
column on an Eskigent nanoLC system coupled to a Thermo LTQ-ETD-Orbitrap.
The Advion Triversa NanoMate served as the nano-ion spray source. Mass spec-
trometry and tandem mass spectrometry (MSMS) data were searched against the
RefSeq human protein database by Sorcerer Sequest (Sage-N Research, Milpitas,
CA). The searched data set was processed using the TPP (trans-proteomics pipe-
line) and ﬁltered with peptide prophet.
PLA. PLA was performed using the Duolink In Situ Red Kit purchased from Sigma
(DUO92101) in accordance with the manufacturer’s instruction. Brieﬂy, trans-
fected cells were washed once with ice-cold PBS, followed by ﬁxation with 4% PFA
for 15min at room temperature. The ﬁxed cells were then washed three times with
PBS and permeabilized with 0.3% Triton X-100 containing PBS for 10min. The
permeabilized cells were blocked with 5% normal goat serum for 1 h at room
temperature. The cells were then incubated with primary antibodies (rabbit anti-
FLAG (CST 14793, 1:300 dilution) and mouse anti-HA (Sigma H9658, 1:300
dilution) diluted in 10% normal goat serum supplemented with 0.1% Tween at 4 C
overnight. Following the incubation, the cells were three times with PBS and then
incubated with two PLA probes (Duolink In Situ PLA Probes Anti-rabbit PLUS
and Anti-Mouse MINUS, Sigma-Aldrich) for 1 h at 37 C. After probe incubation,
the samples were incubated in ligation solution for 1 h at 37 C. After ligation, the
cells were washed with wash buffer A and incubated in ampliﬁcation solution for
2 h at 37 C. The cells were then serially washed twice in 1 wash buffer B,
0.01wash buffer B once, and PBS once, followed by incubation with secondary
antibodies for 1 h at room temperature. Finally, the cells were washed three times
with PBS and mounted in Duolink In Situ Mounting Medium supplemented with
DAPI. Fluorescent images were obtained using a confocal microscope.
Primary cell culture. The astrocyte culture was prepared from 1-day-old neonatal
mice. Brains freed of meninges were dissociated with 1-ml pipettes. Debris was
removed by ﬁltration through a 70-mm cell strainer (Falcon). The cells were cul-
tured in DMEM plus 10% foetal bovine serum (vol/vol) supplemented with
50mgml 1 penicillin and 50mgml 1 streptomycin. Ten days after the initial
culture, cells were stained with antibody against GFAP (Sigma, G3893, 1:500) to
verify the purity of the astrocytes. OPCs were derived from neurospheres. Embryos
were dissected from pregnant mice 14 days after the last recording of a vaginal
plug. Neurospheres were cultured in DMEM/F12 supplemented with B27 (Invi-
trogen) and 20 ngml 1 recombinant mouse epidermal growth factor (R&D).
Floating neurospheres were passaged at a 1:3 ratio in the same medium every 3
days. To produce pure OPCs, neurospheres were dissociated after two–three pas-
sages and plated on poly-D-lysine-coated plates in DMEM/F12 supplemented with
B27 (Invitrogen), 20 ngml 1 FGF and 10 ngml 1 PDGF (Peprotech). The OPC
purity was veriﬁed with anti-Olig2 and CNPase staining (498% of cells were
Olig2þ CNPase at 4 days after culture). For the OPC-astrocyte co-culture,
astrocytes were plated in six-well plates at a density of 2 104 per well in DMEM/
F12 supplemented with B27. On the following day, dissociated neurospheres were
plated together with the astrocytes at a density of 5 105 per well. The culture
medium was further supplemented with 20 ngml 1 FGFþ 10 ngml 1 PDGF to
promote OPC differentiation. The co-culture was maintained for 4 more days
before being subjected to experiments (for example, IL-17 treatment). To generate
NOTCH1 and RBP-J knockout OPCs, neurospheres were prepared from
NOTCH1ﬂ/ﬂ and RBP-J ﬂ/ﬂ embryos. An adenovirus directing the expression of
GFP (control) or Cre was added to the culture medium after neurosphere dis-
sociation to mediate the deletion of ﬂoxed alleles. NOTCH1 and Jagged1-deﬁcient
astrocytes were isolated from NOTCH1 ﬂ/ﬂ and Jagged1 ﬂ/ﬂ neonatal mice, and
deletion was achieved by adenovirus infection as described for the neurosphere.
The Cre deletion was validated in OPCs for NG2-ER-cre. Cultured OPCs were
collected and stained with anti-NG2 for cell sorting of NG2þ OPCs cells. Sorted
cells were lysed, and western blotting was conducted to evaluate RBP-J expression
in NG2þ cells from NG2-ER-cre; RBP-J ﬂ/þ and NG2-ER-cre; RBP-J ﬂ/ﬂ mice.
Real-time PCR. Total RNA was extracted from the spinal cord with TRIzol
(Invitrogen) according to the manufacturer’s instructions. Three micrograms of
total RNA for each sample was reverse-transcribed using SuperScript II Reverse
Transcriptase from Thermo Fisher Scientiﬁc. The resulting complementary DNA
was analysed by real-time polymerase chain reaction (PCR) using SYBR Green
Real-Time PCR Master Mix. All gene expression results are expressed as arbitrary
units relative to the expression of Actb. The fold induction of gene expression in
spinal cord after EAE induction was determined by dividing the relative abundance
of experimental samples by the mean relative abundance of control samples from
naive mice. The primer sequences for RT–PCR are listed in Supplementary Table 1.
Luciferase reporter assay. HeLa cells were transfected with 100 ng of a Hes1-
luciferase reporter construct in a 12-well plate together with the combination of
plasmids indicated in the ﬁgure legends. Forty-eight hours after transfection, the
cells were lysed, and luciferase activity was determined using the luciferase assay
system and chemiluminescent reagents from Promega.
Chromosomal immunoprecipitation. The binding of Act1 and RBP-J to pro-
moters of STEAP4, PTX3, CCL7 and S100A9 was assessed by chromosomal
immunoprecipitation (ChIP) using OPCs co-cultured with Act1 KO astrocytes.
The ChIP assay was performed using the ChIP assay Kit from Active Motif in
accordance with the manufacturer’s instructions. Brieﬂy, a total of 1 107
co-cultured cells was ﬁxed with 1% formaldehyde. Fixed cells were sonicated for
30 s at medium power for 20 cycles, followed by centrifugation. The sonicated
whole-cell extract was diluted in ChIP dilution buffer. The samples were incubated
at 4 C overnight with antibodies against RBP-J (CST 5313, diluted at 1:50), Act1
(Covance, diluted at 1:50) or rabbit IgG (CST Cat No. 3,900, at 1:50) and
A-Sepharose beads (Active Motif). The precipitates were washed and subjected to
DNA extraction followed by RT–PCR analysis of promoter enrichment using the
primers listed in Supplementary Table 1.
Mouse control primers for the Chip assay were purchased from Active Motif
(71011).
Tamoxifen injection to deplete NOTCH1 and RBP-J in vivo. NG2-ER-cre;
NOTCH1 ﬂ/þ and NG2-ER-cre; NOTCH1ﬂ/ﬂ mice and NG2-ER-cre; RBP-J ﬂ/þ
and NG2-ER-cre; RBP-J ﬂ/ﬂ mice (4 weeks old) were injected intraperitoneally with
5mg of tamoxifen per week for at least 4 weeks.
GeneChip Microarray analysis. Five mice in each group were left untreated
(naive group) or adoptively transferred with MOG-reactive Th1 or Th17 cells. Act1
KO mice received only the Th17 adoptive transfer. Twelve days after adoptive
transfer, the mice were killed, and spinal cords were subjected to mRNA extraction
for microarray analysis. Target preparation was performed on a Biomek FXP
(Beckman Coulter, Brea, CA) using a GeneChip HT 30IVT Express Kit (Affymetrix,
Santa Clara, CA) in accordance with the manufacturer’s instruction. Labelled
cRNA was hybridized on an Affymetrix GeneChip HT-MG-430PM-96 (Affyme-
trix). Array hybridization, washing and scanning were performed using GeneTitan
(Affymetrix). Three independent biological replicates were analysed in each
experiment, which yielded consistent results. The t-test was used to assess sig-
niﬁcance, and Po0.05 was deemed signiﬁcant. The data for the normalized
GeneChip analysis are provided in Supplementary Data 1 and the raw data are
deposited in the Gene Expression Omnibus.
Induction and assessment of EAE. Recipient mice were injected with 3.0 107
MOG35–55-reactive Th1 or Th17 cells at 4 h after 500-Rad sublethal irradiation. To
prepare MOG35–55-reactive T cells, donor mice were immunized with MOG35 55
subcutaneously; draining lymph node cells and splenocytes were prepared from
donor mice at 10 days after immunization. The cells were cultured for 5 days with
MOG35–55 at a concentration of 25mgml 1 under either Th1-polarizing condi-
tions (20 ngml 1) rmIL-12, R&D; 2 mgml 1 aIL-23p19, eBioscience) or Th17-
polarizing conditions (20 ngml 1 rmIL-23, R&D). Scoring of EAE symptoms was
performed in a double-blinded manner. Power analysis was performed to deter-
mine the sample size before the experiment. With an average coefﬁcient of variance
of 25%, we determined that n¼ 5 was needed to obtain 90% power for the
detection of a 30% difference between the groups. The mice were weighed and
assigned scores daily for neurological signs according to the following scale: 0, no
disease; 1, decreased tail tone or slightly clumsy gait; 2, tail atony and/or moder-
ately clumsy gait and/or poor slighting ability; 3, limb weakness; 4, limb paralysis;
5, moribund state or death. The control and experimental groups were blinded to
the investigators who recorded the clinical score, ﬂow analysis, histology and Luxol
fast blue (LFB) staining.
Isolation and analysis of CNS inﬂammatory cells. Brains were homogenized in
ice-cold tissue grinders and ﬁltered through a 70-mm cell strainer, and the cells
were collected by centrifugation at 400g for 5min at 4 C. The cells were re-
suspended in 10ml of 30% Percoll (Amersham Bioscience) and centrifuged onto a
70% Percoll cushion in 15-ml tubes at 800g for 30min. The cells in the 30–70%
interface were collected and subjected to ﬂow cytometry. The gross cell population
was ﬁrst gated based on the forward and side scatter for viable, single cell events.
Fluorescence-conjugated monoclonal antibodies against CD4 (clone GK1.5), CD8
(clone 53-6.7), CD45 (clone 30-F11), Ly6G (clone 1A8), CD19 (clone 1D3) and iso-
type controls were purchased from BD Biosciences. F4/80 (clone Cl:A3-1) was
obtained from Serotech. The antibodies were diluted 1:200–1:400 for use.
Histological analysis. All sections used herein were 5-mm thick. For parafﬁn-
embedded tissue, spinal cords collected from phosphate-buffered saline-perfused
mice were ﬁxed in 10% formalin and then dehydrated with 70% alcohol. The
sections were stained with either haematoxylin and eosin (H&E) or LFB to evaluate
inﬂammation and demyelination, respectively. For cytohistochemical staining, the
cells were ﬁxed in 2% PFA for 10min. The cells were further permeabilized with
0.1% Triton X-100 for 10min and then incubated with primary antibody followed
by ﬂuorescence-conjugated secondary antibodies for microscopic analysis. NG2
antibodies were provided by W.B. Stallcup (Burnham Institute for Medical
Research). Histological quantiﬁcation was performed in a double-blinded manner.
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Peptide. Scramble and IL-17RA decoy peptides were synthesized as described38.
The scramble peptide sequence is ‘PRFASPCCVFCTPDVPQSYTNVVLLITIHVV
DQPAKSNVS’, and the decoy peptide sequence is ‘VQVQPFFSSCLNDCLRHAV
TVPCPVISNTTVPKPVADYIP’.
Osmotic pump implantation. Control or IL-17RA decoy peptide was dissolved in
sterile artiﬁcial cerebrospinal ﬂuid (CSF). Micro-osmotic pumps (Alzet) were ﬁlled
with dissolved peptides and placed in the bottom of a 200-ml glass beaker that was
half ﬁlled with sterile 0.9% NaCl in a humidiﬁed 37 C incubator overnight for
activation. Mice were anaesthetized with a ketamine (100mg kg 1) and xylazine
(10mg kg 1) cocktail. Anaesthetized mice were placed in a stereotactic device with
a three-axis chronic micromanipulator. The injection coordinates were 1mm lat-
eral, 0.3mm posterior and 2mm deep to the bregma. The overlying skin was cut to
form a 0.7 cm incision in the head and a 0.5 cm incision in the back of the mouse
right below the neck. The cranium was opened using a compact drill followed by
insertion of the infusion cannula (2mm in depth). Osmotic pumps were implanted
in the back of the mice. A pocket was made to connect the infusion pump so that
the incision site was not directly over the pump. Implanted mice were housed in
separate cages to avoid ﬁghting. Three days after pump implantation, Th17 cells
were adoptively transferred into the mice by intraperitoneal injection.
Statistics. For comparison between two groups, normality was not assessed for the
statistical analysis. Non-parametric statistics were applied to compare differences
between two groups. The Mann–Whitney U-test was used to derive all P values.
The clinical scores in the EAE experiment were analysed with two-way ANOVA
for multiple comparisons. The sample size for the EAE experiment was estimated
by power analysis assuming a normal distribution of the data. No randomization
was performed. Po0.05 was considered signiﬁcant. The results are presented as the
mean, and the error bars represent the s.e.m. technical or biological replicates as
indicated in the ﬁgure legend.
Data availability. All data supporting the ﬁndings of this study are available
within the article and its Supplementary Information ﬁles or from the corre-
sponding authors on reasonable request. The GeneChip microarray data described
in the study have been deposited in the Gene Expression Omnibus under accession
code GSE97035.
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